HOME >> BIOLOGY >> NEWS
Certolizumab pegol demonstrates positive results in two Phase III Crohn's disease trials

Atlanta, Georgia, July 26, 2005 - UCB today announced positive results for the two pivotal Phase III trials (PRECISE 1 and 2) of certolizumab pegol (CDP870) in the induction and maintenance of clinical response in moderate to severe active Crohn'TMs disease. The PRECiSE trials assessed the safety and efficacy of CIMZIATM compared to placebo over a 26 week period, in a total of 1330 patients with active Crohn'TMs disease.

Data from PRECiSE 1 and 2 will be presented in more detail at the major forthcoming gastroenterology medical congresses.

About Crohn'TMs Disease

Crohn'TMs disease is a chronic inflammatory disease of the gastrointestinal tract with the disease typically localized in the terminal part of the ileum (a portion of the small intestine) and right colon (a portion of the large intestine). Crohn'TMs disease affects almost 1 million patients worldwide, with the disease typically appearing early in life. Crohn'TMs disease is characterized by a variety of symptoms, although different in every individual, and may include persistent diarrhea, abdominal pain, and at times loss of appetite/weight, fever or rectal bleeding . Unfortunately there is no single test to diagnose Crohn'TMs disease and because it can often imitate other gastroenterological conditions, patients may experience a lengthy diagnosis process. Although Crohn'TMs disease affects males and females equally of all ages, the most affected in the U.S. are 20-29 year olds and 30-39 year olds . The disease also occurs in young children and adults over 70 years of age. In addition, American Jews of European backgrounds are more likely than the general population to develop Crohn'TMs disease.

Crohn's Disease - United States (Prevalence)

About CIMZIATM

CIMZIATM is a PEGylated Fab'TM fragm
'"/>

Contact: Lisa Garman
Lisa.garman@ucb-group.com
770-970-8569
Ketchum
26-Jul-2005


Page: 1 2

Related biology news :

1. New study demonstrates important role of glia in circadian timing
2. Stowers Institutes Workman Lab demonstrates mechanism for decoding histone modification marks
3. BEMA Fentanyl demonstrates substantial transmucosal delivery
4. Xie Lab demonstrates the role of microRNA pathway
5. Rong Li Lab demonstrates the process of mammalian egg maturation
6. Compelling evidence demonstrates that Hobbit fossil does not represent a new species of hominid
7. OHSU research demonstrates possible health risks for children born to overeating mothers
8. New research demonstrates bone-marrow derived stem cells can reverse genetic kidney disease
9. NYUS Childress demonstrates tool for studying hovering flight at international science meeting
10. Study demonstrates rapid diagnosis of urinary tract infections with biosensor technology
11. Report demonstrates safety of nuclear medicine procedures

Post Your Comments:
(Date:5/18/2013)... Orlando, FL (May 18, 2013) An increasing ... that require interventions to resolve, according to research ... In one study targeting obesity, researchers at the ... have a unique pattern of exhaled breath compared ... in volatile organic compound levels that can be ...
(Date:5/17/2013)... interaction of a group of proteins in the brain ... a new target that could increase cell survival. , ... of Biochemistry and published in the EMBO journal ... lead to new therapies for stroke and other brain ... the team which identified a protein, known as SUMO, ...
(Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
Breaking Biology News(10 mins):New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3SUMO wrestling cells reveal new protective mechanism target for stroke 2New X-ray method shows how frog embryos could help thwart disease 2
(Date:5/17/2013)... occurs when the transplant recipient,s immune system identifies the ... was previously thought that T cells, the immune cells ... known as chemokines in order to migrate to the ... of Clinical Investigation , Fadi Lakkis and colleagues at ... chemokine stimulation of T cells is not required for ...
(Date:5/17/2013)... 2013 - Elsevier, a world-leading provider of scientific, technical ... publication of a recent study in Reproductive ... showing that those with an abnormal chromosomal composition can ... developed to blastocysts, thereby classifying the risk of genetic ... same group has undertaken a retrospective study, using their ...
(Date:5/17/2013)... 17, 2013 •    First of its kind ... sustainability ,     New facility will help solve crop ... Syngenta unveiled its new crop research facility ... RTP Innovation Center. The first of its kind, $72 ... any agricultural climate and precisely measure plant inputs – ...
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
Cached News: